Investors & Media

Investors

Corporate Profile

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.  By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days.  We call this our commitment to “target a better now.”  Our lead product candidate, mirvetuximab soravtansine, is in Phase 3 study for folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer, and in Phase 1b/2 testing in combination regimens. Our novel IGN candidates for hematologic malignancies, IMGN779 and IMGN632, are in Phase 1 studies.

Copyright Nasdaq. Minimum 15 minutes delayed.

Press Releases
Jul 31, 2018
ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference
Jul 27, 2018
ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results

Events & Webcasts

Shareholder Inquiries

Inquiries related to the Company may be directed to the Investor Relations department at our headquarters. Communications related to stock and transfer requirements, including lost stock certificates and change of name or address, should be directed to the Transfer Agent.

Corporate Headquarters

ImmunoGen, Inc.
830 Winter Street
Waltham, MA 02451-1477
Phone: (781) 895-0600
Email: info@immunogen.com

 

Corporate Counsel

Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C.
Boston, MA

Transfer Agent and Registrar

Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, NY 11717
Phone: (877) 830-4936
Fax: (215) 553-5402
E-mail: shareholder@broadridge.com

 

Independent Accountants

Ernst & Young LLP
Boston, MA